Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index; 71 of the 128 sources its claims cite were checked for support.

Irritable bowel syndrome

Abstract

Irritable bowel syndrome is a functional gastrointestinal disorder with symptoms including abdominal pain associated with a change in stool form or frequency. The condition affects between 5% and 10% of otherwise healthy individuals at any one point in time and, in most people, runs a relapsing and remitting course. The best described risk factor is acute enteric infection, but irritable bowel syndrome is also more common in people with psychological comorbidity and in young adult women than in the rest of the general population. The pathophysiology of irritable bowel syndrome is incompletely understood, but it is well established that there is disordered communication between the gut and the brain, leading to motility disturbances, visceral hypersensitivity, and altered CNS processing. Other less reproducible mechanisms might include genetic associations, alterations in gastrointestinal microbiota, and disturbances in mucosal and immune function. In most people, diagnosis can be made on the basis of clinical history with limited and judicious use of investigations, unless alarm symptoms such as weight loss or rectal bleeding are present, or there is a family history of inflammatory bowel disease or coeliac disease. Once the diagnosis is made, an empathetic approach is key and can improve quality of life and symptoms, and reduce health-care expenditure. The mainstays of treatment include patient education about the condition, dietary changes, soluble fibre, and antispasmodic drugs. Other treatments tend to be reserved for people with severe symptoms and include central neuromodulators, intestinal secretagogues, drugs acting on opioid or 5-HT receptors, or minimally absorbed antibiotics (all of which are selected according to predominant bowel habit), as well as psychological therapies. Increased understanding of the pathophysiology of irritable bowel syndrome in the past 10 years has led to a healthy pipeline of novel drugs in development.

Overview

CoChat Summary

TL;DR

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterised by recurrent abdominal pain associated with altered stool form or frequency, affecting 5–10% of otherwise healthy individuals in the community at any one time. Management centres on an empathetic clinical diagnosis with limited investigations, first-line dietary and antispasmodic therapies, and second-line central neuromodulators, secretagogues, 5-HT/opioid-targeted drugs, antibiotics, or psychological therapies for more severe symptoms.

Key findings

  • Global prevalence is commonly estimated at 5–10%, but Rome Foundation 33-nation data using Rome IV criteria found prevalence rates of 2–6%, with a pooled prevalence of 4.1%; where both Rome III and IV were applied, pooled prevalence fell from 10.1% with Rome III to 3.8% with Rome IV.
  • Prior acute enteric infection is the best-recognised risk factor, observed in approximately 10% of patients; a meta-analysis of 45 observational studies reported a four-fold increase in odds of IBS 12 months post-infection (OR 4.2; 95% CI 3.1 to 5.7).
  • In treatment meta-analyses, antispasmodics reduced the risk of remaining symptomatic versus placebo (RR 0.65; 95% CI 0.56 to 0.76) but increased side effects (RR 1.60; 95% CI 1.15 to 2.21); TCAs reduced remaining symptomatic (RR 0.65; 95% CI 0.55 to 0.77) with more adverse events (RR 1.56; 95% CI 1.23 to 1.98); ispaghula husk (RR 0.83; 95% CI 0.73 to 0.94) and peppermint oil (RR 0.54; 95% CI 0.39 to 0.76) were also superior to placebo.
  • Annual direct and indirect IBS-related costs are estimated at up to €8 billion in Europe, ¥123 billion in China, and in excess of $10 billion in the USA.

Methods

  • Narrative review with a stated search of MEDLINE, EMBASE, EMBASE Classic, and the Cochrane Central Register of Controlled Trials over the last 10 years, plus clinicaltrials.gov for unpublished trials, using terms including “irritable bowel syndrome”, “epidemiology”, “pathophysiology”, “diagnosis”, “management”, and “treatment”.
  • Included only English-language publications, selecting articles judged by the authors to be of greatest importance and favouring randomised controlled trials, meta-analyses, and network meta-analyses.
  • Evidence is synthesised narratively across epidemiology, risk factors, pathophysiology, diagnosis, investigations, natural history, and management.

Limitations

  • The paper states that methodological limitations make reliable prevalence estimates difficult, that most risk-factor studies are cross-sectional and lack the temporal element needed to determine cause and effect, and that no universally accepted biomarker for IBS exists.
  • It also states that many first-line drug RCTs are old, have suboptimal methodology and heterogeneous patient selection, and use efficacy endpoints that do not meet current FDA or EMA recommendations; most RCTs are only 12 weeks, so long-term efficacy is unknown.
  • Evident from the text: this is a narrative review, not a systematic review, with article selection based on the authors’ view, English-language restriction, and a 10-year search window; no formal risk-of-bias assessment or PRISMA-style protocol is reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)31548-8

Cites

160 of 160 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

48 Valid · 17 Not valid · 45 Not checked · 39 Own results and interpretations

92 more claims · 33 with their cited sources checked

Create a free account to see all 149 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 15
  • It may state two separate claims as one. 43
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 147 references

Cited by

See all 853

Metadata

Authors
Ford, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M.
Affiliations
  • University of Leeds (GB)
  • Ben-Gurion University of the Negev (IL)
  • Nottingham University Hospitals NHS Trust (GB)
  • Mayo Clinic (US)
Corresponding author
Ford, Alexander C
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-11
Volume
396
Issue
10263
Pages
1675-1688
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4296277377
Cited by
818
References
147
Citations by year
2026: 152 · 2025: 150 · 2024: 147 · 2023: 158 · 2022: 136 · 2021: 74
FWCI
16.08
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
Keywords
irritable bowel syndrome, functional gastrointestinal disorders, gut-brain axis, visceral hypersensitivity, bowel motility disorders, acute intestinal infections, psychological comorbidity, risk factors, diagnosis, patient education, dietary fiber, antispasmodic agents, neuromodulators, serotonin receptor agonists, opioid antagonists, psychotherapy, quality of life, new drug development
MeSH terms
Gastrointestinal Microbiome, Brain, Dietary Fiber, Gastrointestinal Agents, Gastrointestinal Diseases, Humans, Quality of Life, Abdominal Pain, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Irritable bowel syndrome. https://app.cochat.ai/papers/10.1016/s0140-6736(20)31548-8
The paper
Ford, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020). Irritable bowel syndrome. The Lancet. https://doi.org/10.1016/s0140-6736(20)31548-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.